News

Choroideremia Gene Therapy Showing Promise

Researchers at Oxford University have reported successful findings from their Phase 1/2 clinical testing of the CHM gene for treatment of choroideremia. Choroideremia is a rare disease affecting mostly males that leads to blindness. In the multicentre clinical trial, six male patients (aged 35—63 years) all showed improvement after replacement of the malfunctioning gene. The [Read More]

Time Between Lucentis and Eylea Treatments Found To Be Similar

The principal difference between the two leading FDA-approved anti-VEGF drugs, Eylea and Lucentis for treatment of retinal hemorrhage has been accepted as the difference in length of time between injections. A new study, however, found no significant difference in injection scheduling between the drugs. The overall mean days between injections differed by only 1.8 days [Read More]

Low Vision Seniors Are Self-Limiting Their Driving

A new cross-sectional study has concluded that most patients with AMD-related central vision loss continue to drive, but that they demonstrate significant driving restrictions, especially with more severe visual acuity and contrast sensitivity loss. To determine if central visual loss is associated with driving cessation, driving restriction, or other-driver preference, researchers compared two groups of [Read More]